Targeted downregulation of TGF-beta 2 by the antisense compound AP 12009 as immunotherapy for malignant glioma: A Phase IIb study

Schlingensiepen, K. H. and Kunst, M. and Pichler, J. and Parfenov, V. E. and Sastry, K. V. R. and Zaaroor, M. and Rappaport, Z. H. and Hau, Peter and Schlingensiepen, R. and Bogdahn, Ulrich (2005) Targeted downregulation of TGF-beta 2 by the antisense compound AP 12009 as immunotherapy for malignant glioma: A Phase IIb study. In: AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 14-18, 2005, Philadelphia, PA.

Full text not available from this repository.
Item Type: Conference or Workshop Item (UNSPECIFIED)
Additional Information: Konferenz nachgewiesen, aber Beitrag nicht /gup
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Neurologie
Depositing User: Petra Gürster
Date Deposited: 28 Jun 2022 06:25
Last Modified: 28 Jun 2022 06:25
URI: https://pred.uni-regensburg.de/id/eprint/35315

Actions (login required)

View Item View Item